Zacks Investment Research lowered shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) from a buy rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

A number of other analysts have also issued reports on the stock. Redburn Partners upgraded shares of Dipexium Pharmaceuticals to an outperform rating in a research note on Tuesday, August 1st. UBS AG raised shares of Dipexium Pharmaceuticals from a market perform rating to an outperform rating and set a $12.00 price objective for the company in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $9.63.

Dipexium Pharmaceuticals (NASDAQ PLXP) traded down 4.338% during midday trading on Tuesday, hitting $6.395. 13,435 shares of the stock traded hands. Dipexium Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $126.72. The company’s 50-day moving average is $6.53 and its 200 day moving average is $7.55. The firm’s market cap is $55.56 million.

TRADEMARK VIOLATION WARNING: This piece was first published by Marea Informative and is the property of of Marea Informative. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at

Several institutional investors have recently bought and sold shares of the company. Heritage Way Advisors LLC purchased a new stake in shares of Dipexium Pharmaceuticals during the second quarter worth $197,000. University of Texas Investment Managment Co. purchased a new position in Dipexium Pharmaceuticals in the second quarter valued at $385,000. Finally, Susquehanna International Group LLP purchased a new position in Dipexium Pharmaceuticals in the second quarter valued at $1,413,000. 19.68% of the stock is currently owned by institutional investors and hedge funds.

Dipexium Pharmaceuticals Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Stock Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.